Benu Biopharma utilizes a “Virtual” business model, with the oversight of a small cadre of highly skilled and experienced biotechnology managers, that enables early stage compounds or biologics to be moved into the clinic and through clinical proof of principle expeditiously and efficiently.
Benu BioPharma offers biotechnology companies more than 60 years of combined experience in drug and biologic product development, providing advice and experience during the crucial early stages of development. Benu Biopharma provides comprehensive product development, portfolio management and diligence services.
AEM-28 has been extensively validated in the most relevant animal models by a leading academic institution prior to formation of the company. AEM-28 has been granted orphan drug designation from the FDA. >> Visit LipimetiX Development
Inappropriately activated clotting can lead to serious consequences including venous thromboembolism, deep vein thrombosis, stroke and heart attack. The novel drugs being developed by eXIthera, unlike all presently approved anticoagulants/antithrombotics, are expected to prevent thrombosis without causing bleeding. >> Visit eXIthera Pharmaceuticals